Literature DB >> 2025515

Pharmacokinetically determined cyclosporine dosage in young children.

K Hoppu1, O Koskimies, C Holmberg, E L Hirvisalo.   

Abstract

To account for the individual variability in cyclosporine pharmacokinetics and the non-existence of dosing recommendations in young children, we studied the pharmacokinetics of cyclosporine before renal transplantation in ten children aged 1.1-2.5 years, to determine the appropriate individual dose. Our aim was to reach a steady-state cyclosporine blood level of 200-300 micrograms/l, 8 h after a dose in the first days after renal transplantation. Cyclosporine was given as a single oral dose (10 mg/kg) or as a 4-h i.v. infusion (3 mg/kg), and the blood concentration was determined for 24 h by a specific monoclonal radioimmunoassay. The mean terminal cyclosporine half-life (t1/2) was 9.3 h (range 2.8-20.4), blood clearance 10.8 ml/min per kilogram (range 6.8-22.7) and volume of distribution 2.8 l/kg (range 1.4-4.7). The bioavailability of oral cyclosporine was low; the mean amount absorbed was 21.8% of the administered dose (range 11-35). The mean calculated dose needed to attain the intended predose blood cyclosporine level of 200-300 micrograms/l at steady-state was 5 mg/kg per day for i.v. and 21 mg/kg per day for oral administration. In view of the short t1/2, we used three doses/day. The validity of the predicted doses is shown by the mean cyclosporine doses used during the first 10 days after transplantation, which were 93.5% of the calculated oral and 96.6% of the calculated i.v. doses. The observed mean cyclosporine concentration during the same period was 196 micrograms/l.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2025515     DOI: 10.1007/bf00852828

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  11 in total

1.  Renal transplantation in children with congenital nephrotic syndrome of the Finnish type.

Authors:  C Holmberg; H Jalanko; O Koskimies; M Leijala; K Salmela; B Eklund; S Wikström; J Ahonen
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Cyclosporine pharmacokinetics in uremic patients: influence of different assay methods.

Authors:  K L Reynolds; J Grevel; S Y Gibbons; M S Welsh; L P Rutzky; B D Kahan
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

3.  A safer approach to the clinical use of cyclosporine: the predose calculation.

Authors:  F Lokiec; A Fischer; E Gluckman
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

4.  Clinical variability of cyclosporine pharmacokinetics in adult and pediatric patients after renal, cardiac, hepatic, and bone-marrow transplants.

Authors:  C W Clardy; T J Schroeder; S A Myre; N K Wadhwa; A J Pesce; M R First; P T McEnery; W F Balistreri; R E Harris; D B Melvin
Journal:  Clin Chem       Date:  1988-10       Impact factor: 8.327

5.  Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period.

Authors:  G D Morse; M T Holdsworth; R C Venuto; J Gerbasi; J J Walshe
Journal:  Clin Pharmacol Ther       Date:  1988-12       Impact factor: 6.875

6.  Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients.

Authors:  G C Yee; T P Lennon; D J Gmur; M S Kennedy; H J Deeg
Journal:  Clin Pharmacol Ther       Date:  1986-10       Impact factor: 6.875

7.  New automated high-performance liquid chromatographic analysis of cyclosporin A and G in human serum.

Authors:  P E Wallemacq; M Lesne
Journal:  J Chromatogr       Date:  1987-01-23

Review 8.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

9.  Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism.

Authors:  W M Awni; B L Kasiske; K Heim-Duthoy; K V Rao
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

Review 10.  Clinical pharmacokinetics in organ transplant patients.

Authors:  R Venkataramanan; K Habucky; G J Burckart; R J Ptachcinski
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

View more
  9 in total

Review 1.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 2.  Cyclosporin pharmacokinetics in paediatric transplant recipients.

Authors:  G F Cooney; K Habucky; K Hoppu
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

3.  Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.

Authors:  Asher D Schachter; Mark R Benfield; Robert J Wyatt; Paul C Grimm; Robert S Fennell; John T Herrin; David S Lirenman; Ruth A McDonald; Ricardo Munoz-Arizpe; William E Harmon
Journal:  Pediatr Transplant       Date:  2006-12

4.  Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates.

Authors:  S Fanta; S Jönsson; J T Backman; M O Karlsson; K Hoppu
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

5.  Renal transplantation in children with emphasis on young patients.

Authors:  J Laine; C Holmberg; K Salmela; H Jalanko; H Sairanen; K Peltola; K Rönnholm; B Eklund; S Wikström; M Leijala
Journal:  Pediatr Nephrol       Date:  1994-06       Impact factor: 3.714

6.  The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients.

Authors:  Giovanni Montini; Francesca Ujka; Cristina Varagnolo; Luciana Ghio; Fabrizio Ginevri; Luisa Murer; Basile S Thafam; Carla Carasi; Graziella Zacchello; Mario Plebani
Journal:  Pediatr Nephrol       Date:  2006-03-21       Impact factor: 3.714

7.  Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children.

Authors:  E Jacqz-Aigrain; C Montes; P Brun; C Loirat
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 8.  Calcineurin inhibitors in pediatric renal transplant recipients.

Authors:  Guido Filler
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

9.  Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol.

Authors:  Asher D Schachter; K E Meyers; L D Spaneas; J A Palmer; M Salmanullah; J Baluarte; K L Brayman; W E Harmon
Journal:  Pediatr Transplant       Date:  2004-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.